Clinical Trial Update: Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity [Phase 1]

View source ↗

Summary

A Phase I trial evaluating the safety and immune response of a xenogeneic HER2/Neu DNA vaccine in patients with metastatic or high-risk breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Xenogeneic HER2/Neu DNA immunization (HER2/Neu DNA vaccine (xenogeneic))

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING